[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atopic-eczema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atopic-eczema":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,72,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100629818","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-mg-k10-in-participants-who-have-atopic-dermatitis-100629818",false,"NCT07479615","A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis","A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients With Moderate To-Severe Atopic Dermatitis","ADaggio","Inclusion Criteria:\n\n1. Age: ≥12 years, both males and females.\n2. Diagnosed with AD (according to the 2014 American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit, and meeting the following conditions:\n3. Within 6 months prior to the screening visit, the patient has shown an insufficient response to topical medication or is medically unsuitable for topical treatment (e.g., significant side effects or safety risks).\n4. Participants should start a stable dose of moisturizer from the signing of ICF, apply a moisturizer twice daily for at least 7 consecutive days prior to randomization and continue using it throughout the study period.\n5. Women of childbearing age have a negative blood pregnancy test result during the screening period.\n6. Participants and their partners agree to use effective contraception from the time of signing the Informed Consent Form (ICF) until 6 months after the end of treatment ; no donation or freezing of germ cells is allowed from the time of signing the ICF until 6 months after the end of treatment.\n7. The participant voluntarily signs the ICF and can comply with all required visits and study-related procedures outlined in the protocol.\n8. For participants ≥ 12 and \\\u003C 18 years of age at Screening Visit: Parent or legal guardian, as required, has voluntarily signed and dated an informed consent form, approved by an IEC, after the nature of the stud has been explained and the participant's parent or legal guardian has had the opportunity to ask questions.\n\nExclusion Criteria:\n\n1. Body weight \\\u003C 30 kilograms (kg).\n2. The participant currently has a diagnosis of another active skin disease that may affect AD evaluation (e.g., psoriasis or lupus erythematosus).\n3. Known allergies to any component of the investigational drug.\n4. The participant cannot tolerate venipuncture or have a history of needle or blood phobia.\n5. The participant has comorbidities that may require systemic steroid therapy, other intervention measures, or require active and frequent monitoring.\n6. Those with significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematologic, neurologic, and psychiatric disorders that are unstable or not well controlled and are considered clinically significant by the investigator.\n7. Participants with ocular diseases deemed unsuitable for study entry by the investigator, such as a history of atopic keratoconjunctivitis involving the cornea.\n8. Participants are planning to undergo major surgery during the study period, including inpatient and outpatient surgeries.\n9. Patients with malignant tumors within 5 years\n10. Participants with any of the following conditions within the related timeline:\n\n    * Use of biologics\n    * Use of targeted inhibitors (e.g., JAK inhibitors), systemic corticosteroids, cyclosporine, or other immunosuppressants\n    * Use of topical treatments for AD\n    * Receipt of allergen-specific immunotherapy\n    * Vaccination with live or attenuated live vaccines\n    * Participation in another clinical drug study\n    * Previous use of interleukin-4 receptor alpha (IL-4Rα) or interleukin-13 (IL-13) monoclonal antibody drugs\n11. Received systemic (oral or intravenous) antibacterial, antiviral, or antifungal treatment within 4 weeks prior to randomization.\n12. Evidence of active tuberculosis, or previous evidence of active tuberculosis without documented adequate treatment\n13. Diagnosis of active parasitic infection; suspected parasitic infection or high risk of infection unless clinical and (if necessary) laboratory evaluations have ruled out active infection prior to randomization.\n14. Laboratory results at screening showing any of the abnormalities\n15. Abnormal 12-lead electrocardiogram (ECG) at screening\n16. Active hepatitis at screening, or positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) with hepatitis B virus DNA (HBV-DNA) positive, or positive for hepatitis C virus (HCV) antibodies with HCV RNA positive.\n17. History of human immunodeficiency virus (HIV) infection, or positive for HIV antibodies at screening\n18. Positive for Treponema pallidum antibodies (TP-Ab) at screening, except if rapid plasma reagin (RPR) or Toluidine Red Unheated Serum Test (TRUST) results are negative\n19. History of illicit drug use, drug abuse, or excessive alcohol consumption\n20. Women who are breastfeeding, pregnant, or planning to become pregnant or breastfeed during the study period.\n21. Any other conditions that the investigator considers inappropriate for study participation.\n\n    \\-","ALL","12 Years",{"count":20,"type":21},498,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Rationale (What is the reason for this study?) Atopic dermatitis (AD) is a condition that makes the skin dry and itchy and is the most common skin condition that causes redness and irritation.\n\nThe exact cause of AD is unclear but genetic and environmental factors are believed to play a role. Common treatment options for participants with AD include basic skin care, medicine that is applied to the skin, and medicine that works in more than one part of the body. Typically, these treatment options work for participants with AD but some have skin lesions (skin sores or damaged skin) over large areas of the body and do not see an improvement in their AD symptoms. MG-K10 has been shown to be effective in treating participants with moderate-to-severeatopic dermatitis in Phase 2 studies (Chaoying Gu et al.2025) and has already completed a Phase 3 clinical study for adults in China. This study aims to evaluate the efficacy and safety of MG-K10 in the adolenscents and adults with moderate-to-severeatopic dermatitis in global population.\n\nObjectives (goals of the study) and Endpoints (how goals are measured) Check how MG-K10 treatment affects atopic dermatitis Study doctors will look at the safety of MG-K10 and if any side effects are reported by participants when they take it.\n\nCheck how the body processes MG-K10 Check how MG-K10 affects the biomarkers of effect Check how the body's immune system (the body's defense system) reacts to MG-K10",[27,28],"Atopic Dermatitis","Atopic Eczema","NOT_YET_RECRUITING","2026-03-15",{"date":32,"type":33},"2026-03-18","ACTUAL",{"date":35,"type":21},"2026-05-01",{"date":37,"type":21},"2029-01",{"name":39,"class":40},"Shanghai Mabgeek Biotech.Co.Ltd","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100626659","phase-4-efficacy-of-crisaborole-2-cream-versus-placebo-in-mild-to-moderate-atopic-eczema-100626659","NCT07438509","Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema","Evaluation of the Efficacy of Crisaborole 2% Cream Compared to Placebo in the Management of Mild to Moderate Atopic Eczema","CRISA-AD","Inclusion Criteria:\n\n* Age 12 to 50 years\n* Clinically diagnosed mild to moderate atopic dermatitis (ISGA score 2 or 3)\n* Willing and able to apply topical medication twice daily for four weeks\n* Able to provide written informed consent (parental consent for participants under 18 years)\n\nExclusion Criteria:\n\n* Severe atopic dermatitis (ISGA score 4)\n* Use of systemic corticosteroids, immunosuppressants, or antibiotics within the past two weeks\n* Known hypersensitivity to crisaborole or any component of the formulation\n* Pregnant or lactating women\n* Presence of other significant dermatological conditions that may interfere with evaluation (e.g., psoriasis, scabies)\n* Immunocompromised status (e.g., HIV infection, organ transplant recipient)","50 Years",{"count":51,"type":21},270,[53],"PHASE4","This randomized controlled trial (RCT) aims to evaluate the efficacy and safety of Crisaborole 2% cream compared with placebo in patients with mild to moderate atopic dermatitis (AD), also known as atopic eczema. AD is a chronic inflammatory skin condition characterized by itching, redness, and recurrent flares that can significantly impair quality of life.\n\nEligible participants aged 12 to 50 years with mild to moderate AD will be randomly assigned to receive either Crisaborole 2% cream or a placebo cream applied twice daily for four weeks. The primary outcome is treatment success at Day 28, defined using the Investigator's Static Global Assessment (ISGA) as a score of 0 (clear) or 1 (almost clear) with at least a two-grade improvement from baseline.\n\nParticipants will be evaluated at baseline, Day 14, and Day 28. Safety, tolerability, and compliance will also be assessed. The results of this RCT may provide locally relevant evidence to guide the management of mild to moderate AD.",[56,28],"Atopic Dermatitis (AD)",[58,59,60,61],"Mild to Moderate Atopic Dermatitis","Crisaborole","Phosphodiesterase-4 Inhibitor","Topical Therapy","2026-03-04",{"date":64,"type":33},"2026-03-06",{"date":66,"type":21},"2026-03-01",{"date":68,"type":21},"2026-09-01",{"name":70,"class":71},"Jinnah Postgraduate Medical Centre","OTHER_GOV",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100610544","cutaneous-biomarkers-in-atopic-eczema-using-a-non-invasive-micro-suction-device-in-babies-100610544","NCT07228962","Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies","Using a Non-invasive Micro-suction Biomarker Extraction Device to Understand Atopic Eczema in Babies","CARE","Inclusion Criteria:\n\n1. Healthy babies and babies with atopic dermatitis up to 6 months old.\n2. Ability of parents\u002Fguardians\u002Fcaregivers to provide written informed consent for study participation.\n3. Willingness of parents\u002Fguardians\u002Fcaregivers to comply with all study requirements.\n4. Parents\u002Fguardians\u002Fcaregivers competent use of English language.\n\nExclusion Criteria:\n\n1. Parents\u002Fguardians\u002Fcaregivers unable to give informed consent.\n2. Preterm birth (defined as birth before 37 completed weeks gestation).\n3. Significant inflammatory skin disease at birth.\n4. Baby has any other serious health issue.",true,"0 Months","6 Months",{"count":84,"type":21},30,"OBSERVATIONAL","This project aims to establish whether an adapted extraction device is tolerable and will be able to measure chemical signals in baby's ISF. Insight into the chemical profiles found in the skin interstitial fluid (ISF) of healthy and diseased babies will identify signals that can be used to investigate the causes of eczema and propose new preventative strategies and effective treatments.\n\nSpecifically, it aims to:\n\n1. Demonstrate that the developed ISF device can be used to extract biomarkers from the skin of babies non-invasively and is tolerable (not causing significant discomfort, bruising, or blister formation).\n2. Compare the profile of chemical markers present in the ISF of healthy babies with babies that have developed eczema.\n3. Compare the biomarker levels extracted from babies with eczema in lesional and non-lesional skin using the developed ISF device.\n4. Compare the microbiome and metabolome profiles from swabs taken from babies with healthy skin and with eczema in lesional and non-lesional skin (exploratory outcome).",[88,27,28],"Eczema",[88,27,90,91,92,93,94,95],"Immune System","Skin Barrier","Dermatology","Interstitial Skin Fluid","Microbiome","Early life","2026-02-09",{"date":98,"type":33},"2026-02-11",{"date":100,"type":21},"2026-03-31",{"date":102,"type":21},"2027-06-30",{"name":104,"class":105},"King's College London","OTHER",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100550932","a-study-to-evaluate-the-emollient-performance-of-doublebase-once-in-the-treatment-of-atopic-eczema-100550932","NCT06453512","A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema","A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema Using SCORAD, Patient Questionnaires and Skin Hydration Measurements","Inclusion Criteria:\n\n* ii) Patients with atopic eczema (personal history or combined personal and familial atopy), of any severity in accordance with the NICE categorisation set out in the table below.\n\niii) Baseline SCORAD assessment score of at least 15. iv) Patients or their parents\u002F legal guardians must be able to read and understand the patient information sheet and sign the Consent Form\u002FAssent Form.\n\nv) Patients normally managing their eczema by regular and ongoing use of leave-on emollient(s).\n\nvi) Patients who are not currently using systemic or topically applied antibiotics or Doublebase Once.\n\nvii) Patients who are willing to use Doublebase Once, once daily, as their only leave-on emollient, for 4 weeks.\n\nviii) Patients who are willing to continue to use their standard cleansing regime and\u002For Doublebase Once as a soap substitute for the duration of the study.\n\nAdditional inclusion criterion for subgroup for skin hydration assessments:\n\ni) Baseline corneometry measurement of ≤40 arbitrary units.\n\nExclusion Criteria:\n\ni) Are currently using or have used in the previous month, any systemic or topically applied antibiotics or Doublebase Once for their atopic eczema.\n\nii) Have a known history of intolerance or skin sensitivity to any of the ingredients of Doublebase Once (as identified on the patient information sheet and product labelling), or similar products.\n\niii) Currently participating in any other ongoing research studies or have participated in a study in the previous 30 days.\n\niv) Patients, or their parents\u002F legal guardians, who may have difficulties completing the questionnaire, which will be written in English only.\n\nv) Employees of the Sponsor or Investigators, or any immediate family member (partner, offspring, parents, siblings, or sibling's offspring) of such employees.\n\nvi) Patients with any medical condition which, in the opinion of the Investigator, may adversely influence their ability to participate in the study.",{"count":114,"type":21},65,[116],"NA","A 4 week, open label, multi-centre (GP setting), post market clinical follow-up study with Doublebase Once in patients of any age and any severity of atopic eczema.\n\nThe study will involve patients who are already using emollients as part of their treatment regime, switching to Doublebase Once. Patients will ideally apply the product once daily for 4 weeks and SCORAD assessments will be performed, and patient questionnaires will be completed. A subgroup of adult patients (up to 15 patients) will also undergo skin hydration measurements for the first 8 days to evaluate objective measurements of skin hydration in patients with atopic eczema.\n\nPhotographs of the same, representative area of eczema will also be taken for all patients at baseline and after 4 weeks of using Doublebase Once.",[28],"RECRUITING","2025-03-13",{"date":122,"type":33},"2025-03-18",{"date":124,"type":33},"2024-10-30",{"date":126,"type":21},"2025-10-01",{"name":128,"class":40},"Dermal Laboratories Ltd",1]